Ionis Pharmaceuticals, Inc. (IONS), a commercial-stage biotechnology company, announced the appointment of Ludwig Hantson as a Board of Director, effective immediately.
Hantson brings more than 30 years of leadership experience from biopharmaceutical and medical device companies. He served as the Chief Executive Officer and Board member of Alexion between 2017 and 2021, prior to its acquisition by AstraZeneca.
He also served as a president of Baxter Bioscience and its spin-off Baxalta as a Chief Executive Officer and board member.
Brett P. Monia, CEO of Ionis, commented, "His experience leading complex global organisations across rare and speciality diseases will be invaluable as Ionis advances our commercial medicines and innovative pipeline and enters a period of accelerated growth and value creation."
The company recently announced the retirement of Joseph Wender and Lynne Parshall, who were long-serving directors of Ionis.
Ionis has traded between $34.78 and $86.74 over the last year.
Ionis is currently trading at $74.17, down 0.42%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.